Skip NavigationSkip to Content

Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy

  1. Author:
    Nijhuis, M.
    Schuurman, R.
    de Jong, D.
    Erickson, J.
    Gustchina, E.
    Albert, J.
    Schipper, P.
    Gulnik, S.
    Boucher, C. A. B.
  2. Author Address

    Boucher CAB Univ Utrecht Hosp, Eijkman Winkler Inst, Dept Virol Heidelberglaan 100 NL-3584 CX Utrecht Netherlands Univ Utrecht Hosp, Eijkman Winkler Inst, Dept Virol NL-3584 CX Utrecht Netherlands NCI, Frederick Canc Res & Dev Ctr, SAIC Frederick, MD USA Swedish Inst Infect Dis Control, Dept Clin Virol S-10521 Stockholm Sweden
    1. Year: 1999
  1. Journal: Aids
    1. 13
    2. 17
    3. Pages: 2349-2359
  2. Type of Article: Article
  1. Abstract:

    Objective: It is thought as a consequence of continuous replication, HIV-1 has acquired an optimal fitness state and that suboptimal antiretroviral therapy selects for drug resistant variants which show impaired Fitness in the absence of the drug. In this paper we studied the evolution and fitness of viral populations appearing in a patient who received protease monotherapy. Methods: Two factors contributing to fitness, drug resistance and protease catalytic activity, were studied at the enzymatic and virological level. Results: The first drug resistant viral variants that were selected in vivo harboured one to three protease substitutions. These mutants showed reduced protease activity and consequently a reduction in viral replication capacity. During continued in vivo replication of these viruses in the presence si the drug, novel variants harbouring additional substitutions in the viral protease appeared. These variants did not display any further increase in drug resistance but demonstrated clearly increased protease activity. Consequently the replication capacity of these viruses was raised to a level at which they replicated better than the original wild-type virus. Conclusion: This study indicates that the viral population in the patient does not have to represent the fittest possible variants, and thus antiretroviral therapy may drive the viral population first through a lower fitness level and then to a higher fitness level. (C) 1999 Lippincott Williams & Wilkins. [References: 56]

    See More

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel